RELA (Ab-468) Antibody

What is RELA and why is it important in cellular signaling?

RELA, also known as transcription factor p65 or NF-κB p65 subunit, is a critical component of the NF-κB transcription factor complex. It functions as the endpoint of numerous signal transduction pathways initiated by various stimuli related to inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis. NF-κB exists as homo- or heterodimeric complexes formed by Rel-like domain-containing proteins including RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL, and NFKB2/p52, with the heterodimeric RELA-NFKB1 complex being the most abundant. These dimers bind to κB sites in the DNA of target genes with varying affinities and specificities, acting as either transcriptional activators or repressors depending on the dimer combination .

What is the significance of serine 468 phosphorylation in RELA?

Serine 468 (S468) is a critical phosphorylation site in the RELA protein that plays an important role in regulating NF-κB-mediated transcriptional activity. This site-specific phosphorylation contributes to the fine-tuning of NF-κB signaling, affecting how the transcription factor complex interacts with DNA and other regulatory proteins. Antibodies that specifically recognize the phosphorylated form of RELA at S468 (pS468) are valuable tools for studying the activation state of NF-κB signaling in various biological contexts and disease models .

How does RELA (Ab-468) antibody differ from phospho-specific RELA antibodies?

RELA (Ab-468) antibody typically recognizes the region around amino acid position 468 of the RELA protein regardless of its phosphorylation status. In contrast, phospho-specific antibodies like anti-phospho-NF-κB p65 (Ser468) specifically bind only when serine 468 is phosphorylated. The key difference is in epitope recognition:

• RELA (Ab-468) antibody: Recognizes the sequence around position 468 (e.g., peptide sequence around aa.466~470 L-A-S-V-D in human NFkB-p65)

• Phospho-RELA (pS468) antibody: Specifically recognizes RELA only when serine 468 is phosphorylated

This distinction is crucial for experimental design when determining whether to measure total RELA protein or specifically its phosphorylated form as an indicator of activation .

What are the recommended applications for RELA (Ab-468) antibody?

Based on the technical data, RELA (Ab-468) antibody has been validated for multiple research applications with specific recommended dilutions:

The antibody has demonstrated reactivity with human, mouse, and rat samples, making it versatile for comparative studies across these species .

What are the optimal storage conditions and handling protocols for maintaining antibody activity?

To maintain optimal antibody activity:

• Store aliquoted antibody at -20°C for long-term storage to prevent freeze-thaw cycles

• For short-term storage (up to 2 weeks), refrigerate at 2-8°C

• When preparing working dilutions, use freshly thawed aliquots

• After initial thawing, prepare small aliquots to avoid repeated freeze-thaw cycles

• Store in buffer conditions specified by the manufacturer (typically PBS with preservatives like sodium azide and glycerol)

• Follow manufacturer's recommendations for thawing procedure

Most RELA antibodies are supplied in buffers containing glycerol (typically 50%) and preservatives like sodium azide (0.02-0.09%) at pH 7.3-7.4, which helps maintain stability .

How should I validate the specificity of RELA (Ab-468) antibody in my experimental system?

Validating antibody specificity is crucial for reliable results. Consider implementing these approaches:

• Positive controls: Use cell lines known to express RELA (e.g., HeLa, 293, HT29 cells)

• Stimulation controls: Compare unstimulated vs. stimulated cells (e.g., with TNF-α or IL-1β to activate NF-κB signaling)

• Knockdown/knockout validation: Test the antibody in RELA-knockdown or knockout samples

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding

• Multiple detection methods: Compare results across different applications (WB, IHC, IF)

• Cross-reactivity assessment: Test the antibody against related proteins in the NF-κB family

Appropriate positive controls include human breast carcinoma tissue for IHC applications, as demonstrated in validation studies .

How should I design experiments to study RELA phosphorylation dynamics?

To effectively study RELA phosphorylation dynamics:

• Time-course experiments: Stimulate cells with appropriate agonists (TNF-α, IL-1β, LPS) and collect samples at multiple time points (5min, 15min, 30min, 1h, 2h, 4h)

• Parallel antibody approach: Use both phospho-specific (pS468) and total RELA antibodies to calculate phosphorylation ratios

• Inhibitor studies: Include specific pathway inhibitors (IKK inhibitors, proteasome inhibitors) to validate pathway-specific effects

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions to track RELA translocation alongside phosphorylation

• Quantitative analysis: Employ quantitative methods like densitometry for Western blots to measure relative phosphorylation levels

• Protein-protein interaction: Consider immunoprecipitation to examine how phosphorylation affects RELA's interaction with other proteins

This comprehensive approach allows tracking of both phosphorylation status and functional consequences in the context of NF-κB signaling .

What controls should be included when using RELA (Ab-468) antibody in Western blotting?

When performing Western blotting with RELA (Ab-468) antibody, include these essential controls:

• Positive control: Cell lysate known to express RELA (HeLa, 293, HT29 cells are validated options)

• Negative control: If available, RELA-knockout or knockdown cell lysate

• Loading control: Antibody against housekeeping protein (β-actin, GAPDH, α-tubulin)

• Molecular weight marker: To confirm detection at expected size (~60 kDa)

• Stimulation control: Paired stimulated/unstimulated samples (e.g., TNF-α treatment to increase RELA expression)

• Secondary antibody control: Sample lane with secondary antibody only to detect non-specific binding

• Blocking peptide control: Antibody pre-incubated with immunizing peptide to verify specificity

These controls help validate the specificity of bands observed in experimental samples and provide necessary context for data interpretation .

How can I optimize immunohistochemistry protocols using RELA (Ab-468) antibody?

For optimal IHC results with RELA (Ab-468) antibody:

• Antigen retrieval optimization:

  • Test both heat-mediated (citrate buffer, pH 6.0) and enzymatic retrieval methods

  • Optimize retrieval time (10-30 minutes) and temperature

• Antibody dilution optimization:

  • Start with recommended range (1:50-1:200)

  • Prepare a dilution series to determine optimal signal-to-noise ratio

• Incubation conditions:

  • Test different incubation times (1 hour at room temperature vs. overnight at 4°C)

  • Determine optimal washing procedures (buffer composition, number of washes)

• Detection system selection:

  • Compare DAB-based vs. fluorescent detection systems

  • For low abundance targets, consider signal amplification methods

• Counterstaining optimization:

  • Adjust hematoxylin counterstaining time for optimal nuclear visualization

  • For fluorescent detection, select appropriate nuclear counterstain (DAPI, Hoechst)

• Positive and negative controls:

  • Include known positive tissue (e.g., human breast carcinoma)

  • Include negative control without primary antibody

Successful IHC staining of human breast carcinoma tissue has been documented, providing a useful reference for expected staining patterns .

What are common issues when using RELA (Ab-468) antibody and how can they be resolved?

When troubleshooting, make only one methodological change at a time to identify the specific variable affecting results .

How can I differentiate between total RELA and phosphorylated RELA in my experiments?

To effectively differentiate between total and phosphorylated RELA:

• Parallel sample processing: Run identical samples on separate blots or slides

• Antibody selection: Use total RELA antibody (like RELA Ab-468) on one set and phospho-specific antibody (like phospho-S468) on another

• Phosphatase treatment controls: Treat one sample set with lambda phosphatase to remove phosphorylation

• Stimulation paradigm: Include samples from cells stimulated to induce phosphorylation alongside unstimulated controls

• Normalization approach: Calculate the ratio of phospho-RELA to total RELA to determine relative phosphorylation levels

• Sequential probing: For Western blots, strip and reprobe the same membrane with total RELA antibody after phospho-RELA detection

This comparative approach enables assessment of both absolute protein levels and the proportion of RELA that is phosphorylated under various experimental conditions .

What considerations should be made when designing multiplex immunofluorescence experiments with RELA (Ab-468) antibody?

For successful multiplex immunofluorescence with RELA (Ab-468) antibody:

• Antibody compatibility:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential staining with complete stripping between rounds

• Spectral considerations:

  • Choose fluorophores with minimal spectral overlap

  • Include single-stained controls for spectral unmixing/compensation

• Antigen abundance balancing:

  • Pair high-abundance targets with lower-intensity fluorophores

  • Adjust exposure settings for each channel independently

• Order of antibody application:

  • Apply antibodies to low-abundance targets first

  • Consider tyramide signal amplification for dim signals

• Blocking strategy:

  • Use species-specific blocking between sequential antibody applications

  • Consider Fab fragment blocking for same-species antibodies

• Controls:

  • Include single-stained samples for each antibody

  • Use substrate controls without primary antibody

  • Consider fluorescence minus one (FMO) controls

• Analysis approach:

  • Employ colocalization analysis software

  • Quantify nuclear vs. cytoplasmic RELA distribution

This approach enables studying RELA in the context of other proteins in the same sample .

How can RELA (Ab-468) antibody be used to study non-canonical NF-κB signaling pathways?

While RELA primarily functions in the canonical NF-κB pathway, RELA (Ab-468) antibody can be valuable for studying non-canonical pathway interactions:

• Crosstalk analysis: Examine how canonical (RELA-dependent) and non-canonical (RELB/p52-dependent) pathways interact by:

  • Immunoprecipitating RELA and probing for non-canonical components

  • Studying differential phosphorylation patterns during pathway activation

  • Examining nuclear translocation kinetics after selective pathway stimulation

• Sequential activation studies:

  • Use temporal stimulation with pathway-specific activators (TNF-α for canonical, CD40L for non-canonical)

  • Track RELA phosphorylation and localization over time

  • Correlate with activation of non-canonical components

• Inhibitor-based dissection:

  • Apply pathway-selective inhibitors to isolate canonical vs. non-canonical effects

  • Monitor RELA phosphorylation status and binding partner interactions

• Co-immunoprecipitation approaches:

  • Use RELA (Ab-468) antibody to pull down complexes

  • Probe for non-canonical pathway components (RELB, p52)

  • Map interaction domains and phosphorylation dependencies

This multi-faceted approach can reveal complex regulatory relationships between canonical and non-canonical NF-κB signaling networks .

How does RELA phosphorylation at S468 differ functionally from other phosphorylation sites in regulating NF-κB activity?

RELA contains multiple phosphorylation sites that regulate its activity in distinct ways:

• Site-specific effects:

  • S468 phosphorylation often has inhibitory effects on specific target gene subsets

  • S536 phosphorylation (in the transactivation domain) generally enhances transcriptional activity

  • S276 phosphorylation affects DNA binding and cofactor recruitment

• Kinase specificity:

  • S468 is targeted by IKKβ during early TNF-α stimulation and by GSK3β during later phases

  • S536 is primarily phosphorylated by IKKβ during inflammatory signaling

  • Different kinases create distinct phosphorylation patterns that encode specific functional outcomes

• Temporal dynamics:

  • Phosphorylation at different sites occurs with distinct kinetics

  • S468 phosphorylation may act as a negative feedback mechanism to terminate NF-κB signaling

• Gene-specific regulation:

  • S468 phosphorylation selectively represses certain NF-κB target genes while leaving others unaffected

  • The combination of phosphorylation at multiple sites creates a "phosphorylation code" for gene-specific regulation

• Protein interaction effects:

  • Different phosphorylation sites alter RELA's interaction with cofactors and chromatin modifiers

  • S468 phosphorylation may recruit specific corepressors to subsets of target genes

Understanding these site-specific effects is crucial for interpreting results when using phospho-specific antibodies in research .

What insights can be gained from combining RELA (Ab-468) antibody with cutting-edge techniques like mass cytometry or super-resolution microscopy?

Integrating RELA (Ab-468) antibody with advanced technologies enables unprecedented insights:

• Mass cytometry (CyTOF) applications:

  • Simultaneously measure RELA with dozens of other signaling proteins at single-cell resolution

  • Create high-dimensional maps of NF-κB pathway activation across heterogeneous cell populations

  • Correlate RELA status with cell surface markers, transcription factors, and phospho-proteins

  • Identify rare cell populations with unique NF-κB signaling states

• Super-resolution microscopy advantages:

  • Visualize nanoscale organization of RELA within nuclear transcriptional complexes

  • Track dynamic assembly/disassembly of RELA-containing enhanceosomes

  • Map spatial relationships between RELA and chromatin structures

  • Observe real-time translocation with unprecedented spatial resolution

• Single-cell proteogenomic integration:

  • Correlate RELA protein levels and phosphorylation with transcriptional outputs

  • Link signaling states to cell-specific gene expression patterns

  • Create causal models connecting RELA activity to downstream effects

• Proximity labeling approaches:

  • Combine with BioID or APEX2 proximity labeling to map RELA interactome

  • Identify context-specific and phosphorylation-dependent interaction partners

These advanced applications move beyond traditional biochemical approaches to provide systems-level understanding of RELA function in complex biological contexts .

How can RELA (Ab-468) antibody contribute to understanding the role of NF-κB in COVID-19 pathogenesis?

Recent research demonstrates important applications of RELA antibodies in COVID-19 research:

• Inflammatory signaling dynamics:

  • Track NF-κB activation in response to SARS-CoV-2 infection in different cell types

  • Correlate RELA phosphorylation status with cytokine production and disease severity

  • Examine how viral proteins interact with and modulate the NF-κB pathway

• Therapeutic target identification:

  • Use RELA antibodies to screen for compounds that modulate NF-κB activation in COVID-19 models

  • Assess effects of existing anti-inflammatory drugs on SARS-CoV-2-induced NF-κB signaling

  • Identify pathway-specific intervention points that might reduce hyperinflammation

• Cross-protective immunity analysis:

  • Study how prior endemic coronavirus exposure shapes NF-κB responses to SARS-CoV-2

  • Examine antibodies against canonical and non-canonical viral antigens in relation to NF-κB activation

  • Investigate how pre-existing immune memory affects inflammatory signaling through NF-κB

Research has shown that antibody responses to both canonical and non-canonical SARS-CoV-2 antigens, as well as cross-reactive responses to endemic coronaviruses, correlate with COVID-19 outcomes. These responses may modulate NF-κB-driven inflammation, with higher IgA antibodies against specific targets associated with improved survival in severe cases .

How might advances in antibody engineering improve future versions of RELA (Ab-468) antibody?

Emerging antibody engineering technologies could enhance RELA (Ab-468) antibody performance:

• Increased specificity:

  • Integration of recombinant antibody technology for more consistent performance

  • Single-chain variable fragment (scFv) derivatives for improved tissue penetration

  • Site-specific mutations to enhance epitope recognition while reducing non-specific binding

• Multifunctionality:

  • Bispecific formats that simultaneously target RELA and interacting proteins

  • Intrabodies designed for subcellular compartment-specific recognition

  • Antibody-enzyme fusion proteins for proximity-based labeling of RELA interaction partners

• Enhanced signal detection:

  • Direct fluorophore conjugation with optimal dye-to-protein ratios

  • Photoswitchable tags for super-resolution microscopy

  • Split-fluorescent protein complementation for visualizing protein interactions

• Temporal control:

  • Optogenetic antibody systems that can be activated with light

  • Chemically inducible binding for temporal control of antibody function

  • Degradation-targeting antibody conjugates to selectively remove phosphorylated RELA

These advances could transform RELA antibodies from passive detection tools into active research reagents that enable precise manipulation of NF-κB signaling dynamics .

What are emerging techniques for monitoring RELA dynamics in live cells, and how might current antibodies be adapted for these applications?

Cutting-edge approaches for studying live-cell RELA dynamics include:

• Nanobody development:

  • Convert conventional RELA antibodies into smaller nanobody formats

  • Engineer cell-permeable versions for live intracellular imaging

  • Create flash-tag fusions for pulse-chase labeling of newly synthesized RELA

• CRISPR-based tagging:

  • Develop knock-in strategies to tag endogenous RELA with fluorescent proteins

  • Create split-fluorescent protein systems for visualizing RELA interactions

  • Implement degron-based approaches for rapid RELA depletion

• Biosensor development:

  • Design FRET-based sensors that detect RELA phosphorylation status

  • Create conformation-sensitive probes that distinguish active from inactive RELA

  • Develop transcriptional reporters that reflect RELA binding to specific promoters

• Optogenetic control:

  • Engineer light-responsive RELA variants for spatiotemporal activation

  • Create optically controlled inhibitors of specific RELA phosphorylation events

  • Implement photoactivatable degrons for precise RELA degradation

These approaches would complement traditional antibody-based detection methods by adding the dimension of temporal dynamics and subcellular resolution to RELA studies .

How can machine learning and computational approaches enhance the interpretation of data generated using RELA (Ab-468) antibody?

Advanced computational methods can extract deeper insights from RELA antibody data:

• Image analysis automation:

  • Deep learning algorithms for unbiased quantification of nuclear vs. cytoplasmic RELA

  • Computer vision approaches for detecting subtle changes in RELA localization patterns

  • Automated classification of cell phenotypes based on RELA staining characteristics

• Multi-omics data integration:

  • Correlative analysis of RELA antibody data with transcriptomics, proteomics, and epigenomics

  • Network modeling to predict functional outcomes of observed RELA phosphorylation patterns

  • Causal inference methods to distinguish drivers from passengers in NF-κB signaling cascades

• Predictive modeling:

  • Develop computational models that predict RELA phosphorylation based on upstream signals

  • Create in silico simulations of how phosphorylation at different sites affects RELA function

  • Generate testable hypotheses about context-dependent RELA regulation

• Antibody performance optimization:

  • Machine learning algorithms to identify optimal staining conditions across sample types

  • Automated quality control systems for antibody validation

  • Computational correction of batch effects in large-scale antibody-based studies

These computational approaches transform descriptive antibody data into predictive models with mechanistic insights .

What are the key considerations for selecting the optimal RELA antibody for specific research applications?

When selecting a RELA antibody for your research:

• Research question alignment:

  • For total RELA detection: Choose antibodies like RELA (Ab-468) that recognize the protein regardless of modification

  • For activation studies: Select phospho-specific antibodies like anti-phospho-S468

  • For localization studies: Ensure the antibody works well in IF/IHC applications

• Technical specifications:

  • Verify species reactivity matches your experimental system (human, mouse, rat)

  • Confirm validated applications (WB, IHC, IF, IP, ELISA, FC)

  • Check recommended dilutions and optimize for your specific application

• Validation evidence:

  • Review images of expected results provided by manufacturers

  • Look for evidence of specificity testing (knockout controls, phosphatase treatment)

  • Consider published literature using the same antibody

• Epitope considerations:

  • Determine if the epitope might be masked by protein interactions

  • Check if post-translational modifications affect epitope recognition

  • For phospho-specific antibodies, verify exact residue and modification

• Format appropriateness:

  • Select unconjugated antibodies for flexible detection methods

  • Choose direct conjugates for multiplexing applications

  • Consider monoclonal for consistency or polyclonal for stronger signals

This systematic selection process ensures the antibody is fit-for-purpose in your specific experimental context .

What is the recommended workflow for validating and implementing RELA (Ab-468) antibody in a new experimental system?

Follow this comprehensive validation workflow when implementing RELA antibody in a new system:

• Initial characterization:

  • Perform titration experiments to determine optimal concentration

  • Test multiple positive control samples with known RELA expression

  • Verify expected molecular weight and staining pattern

• Specificity verification:

  • Include negative controls (knockdown/knockout if available)

  • Test with blocking peptide competition

  • Compare with alternative RELA antibodies targeting different epitopes

• Functional validation:

  • Demonstrate appropriate response to NF-κB activators (TNF-α, IL-1β)

  • Verify inhibition with pathway blockers (IKK inhibitors)

  • Confirm concordance between protein levels and cellular responses

• Reproducibility assessment:

  • Test batch-to-batch consistency

  • Establish standardized protocols with detailed methods

  • Determine experimental variability through repeated measurements

• System-specific optimization:

  • Fine-tune protocols for your specific cell type or tissue

  • Determine optimal sample preparation methods

  • Document all parameters for future reference

This structured approach ensures reliable antibody performance and facilitates troubleshooting if issues arise later .

How can researchers ensure reproducibility and reliability when using RELA (Ab-468) antibody across different studies?

To maximize reproducibility in RELA antibody-based research:

• Detailed documentation:

  • Record complete antibody information (catalog number, lot, clonality, host)

  • Document exact experimental conditions (dilutions, incubation times, buffers)

  • Maintain detailed protocols with all technical parameters

• Quality control measures:

  • Include consistent positive and negative controls in every experiment

  • Implement regular antibody validation checks

  • Monitor storage conditions and expiration dates

• Standardized reporting:

  • Follow field-specific guidelines for antibody reporting in publications

  • Include validation data in supplementary materials

  • Share detailed protocols through repositories or protocol-sharing platforms

• Sample preparation consistency:

  • Standardize cell culture conditions and treatments

  • Use consistent lysis buffers and extraction protocols

  • Apply uniform fixation and permeabilization methods

• Quantification approaches:

  • Employ consistent image acquisition settings

  • Use standardized quantification methods

  • Include calibration standards where applicable

• Statistical considerations:

  • Define adequate sample sizes through power analysis

  • Apply appropriate statistical tests

  • Report all replicates and experimental variations